Infl ammation and haemostasis are interrelated pathophysiologic processes that considerably aff ect each other. In this bidirectional relationship, infl ammation leads to activation of the haemostatic system that in turn also considerably infl uences infl ammatory activity. Such, the haemostatic system acts in concert with the infl ammatory cascade creating an infl ammation-haemostasis cycle in which each activated process promotes the other and the two systems function in a positive feedback loop. The extensive crosstalk between immune and haemostatic systems occurs at level of all components of the haemostatic system including vascular endothelial cells, platelets, plasma coagulation cascade, physiologic anticoagulants and fi brinolytic activity. During infl ammatory response, infl ammatory mediators, in particular proinfl ammatory cytokines, play a central role in the eff ects on haemostatic system by triggering its disturbance in a number of mechanisms including endothelial cell dysfunction, increased platelet reactivity, activation of the plasma coagulation cascade, impaired function of physiologic anticoagulants and suppressed fi brinolytic activity. The two examples of pathophysiologic processes in which the tight interdependent relationship between infl ammation and haemostasis considerably contribute to the pathogenesis and/or progression of disease are systemic infl ammatory response to infection or sepsis and acute arterial thrombosis as a consequence of ruptured atherosclerotic plaque. Close links between infl ammation and haemostasis help explain the prothrombotic tendency in these two clinical conditions in which infl ammation shifts the haemostatic activity towards procoagulant state by the ability of proinfl ammatory mediators to activate coagulation system and to inhibit anticoagulant and fi brinolytic activities. This review summarizes the current knowledge of the complex interactions in the bidirectional relationship between infl ammation and haemostasis.
Introduction
Infl ammation and haemostasis are tightly interrelated pathophysiologic processes that considerably aff ect each other. In this bidirectional relationship, infl ammation leads to activation of the haemostatic system that in turn also considerably infl uences infl ammatory activity (1, 2) . Close interaction between immune and haemostatic systems is an attempt to restore normal tissue function following injury. Local activation of the haemostatic system is an essential part of the host defence in both infectious and non-infectious infl ammatory states. However, an exaggerated and insuffi ciently controlled haemostatic activity induced by infl ammation may appreciably contribute to disease severity. The two examples of clinical conditions in which the tight interdependent relationship between infl ammation and haemostasis considerably contribute to the pathogenesis and/or progression of disease are systemic infl ammatory response to infection or sepsis and acute arterial thrombosis as a consequence of ruptured atherosclerotic plaque. Close links between infl ammation and haemostasis help explain the prothrombotic tendency in these two clinical conditions. Infl ammation shifts the haemostatic activity towards procoagulant state by the ability of proinfl ammatory mediators to activate coagulation system and to inhibit anticoagulant and fi brinolytic activities. Once the activation of haemostatic system occurs in infl ammatory states, amplifi cation of the haemostatic disorder can result in thrombosis and organ damage. In turn, uncontrolled activation of the haemostatic system can also amplify the initial infl ammatory response thus causing additional organ injury. Such, the haemostatic system acts in concert with the infl ammatory cascade creating an infl ammation-haemostasis cycle in which each activated process promotes the other and the two systems function in a positive feedback loop. The goal of infl ammation is to restore the integrity of threatened or damaged tissues because of injury or infectious pathogens. On the other hand, haemostasis is a physiological defence mechanism to stop bleeding due to vessel wall damage (3) . Activated by vessel wall injury, the haemostatic system consists of a complex network of individual components. Vascular endothelial cells (ECs) and platelets constitute primary haemostasis resulting with a formation of platelet clot. This process is followed by an activation of the plasma coagulation cascade, so called secondary haemostasis that induces a formation of a fi brin clot. The net result of the haemostatic activation is stable platelet-fi brin clot. These processes are fi rmly regulated by physiologic anticoagulant mechanisms that keep activation of the coagulation system under control and by fi brinolytic system which is responsible for degradation of the platelet-fi brin clot which has fulfi lled its function (4) . In recent years, various molecular mechanisms that play a role in the bidirectional relationship between infl ammation and haemostasis have been intensively investigated and elucidated. This review summarizes the current knowledge of the complex interactions in the bidirectional relationship between these two interrelated processes.
Mechanisms by which infl ammation induces disturbance of the haemostatic system
The extensive crosstalk between immune and haemostatic systems occurs at the level of all components of the haemostatic system including vascular ECs, platelets, plasma coagulation cascade, physiologic anticoagulant pathways and fi brinolytic activity. During an infl ammatory response, infl ammatory mediators, in particular proinfl ammatory cytokines, play a central role in the eff ects on haemostatic system (5, 6) . The main mediators of infl ammation-induced activation of the haemostatic system are proinfl ammatory cytokines tumour necrosis factor-alpha (TNF-α), interleukin 1 (IL-1) and interleukin 6 (IL-6) (7). Infl ammatory mediators trigger disturbance of the haemostatic system in a number of mechanisms including endothelial cell dysfunction, increased platelet activation, tissue factor (TF) mediated activation of the plasma coagulation cascade, impaired function of physiologic anticoagulant pathways and suppressed fi brinolytic activity (Figure 1 ).
Dysfunction of vascular endothelial cells
Vascular ECs are actively involved in haemostasis. In physiological conditions, intact endothelium functions as an antithrombotic surface thus preventing inappropriate activation of coagulation. ECs are the main producer of components with proinfl ammatory, procoagulant and antifi brinolytic activities, as well as of those with the opposite actions, i.e. anticoagulant, anti-infl ammatory and profi brinolytic properties (Table 1 ). All these components are essential in maintaining a physiological balance involved in the regulation of the haemostatic system.
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Irrespective of its aetiology, infl ammation leads to an imbalance between proinfl ammatory and procoagulant and anti-infl ammatory and anticoagulant properties of the endothelium thus contributing to disturbance of the haemostatic system. Once activated or injured, ECs secrete into the local environment mostly procoagulant or antifi brinolytic components, such as von Willebrand factor (vWF), thromboxane A2 (TXA2) or plasminogen activator inhibitor-1 (PAI-1)) while the expression or secretion of components with anticoagulant and profi brinolytic properties is signifi cantly reduced ( Figure 2 ). In addition, activated ECs can express at their surface tissue factor (TF) and adhesion molecules such as P-and E-selectins, vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) ( Figure 2 ). Adhesion molecules have important role in mediating interaction of neutrophils and platelets with endothelium, thus also promoting the infl ammatory and haemostatic responses. As a result of disturbed balance due to infl ammation, the function of ECs shifts from an anticoagulant, anti-infl ammatory and vasodilatatory phenotype to a proinfl ammatory and procoagulant state. Such, in infl ammatory states the endothelium serves as an important interface between infl ammation and inappropriate activation of the haemostatic system (8).
Proinflammatory procoagulant antifibrinolytic components Antiinflammatory anticoagulant profibrinolytic components
Endothelial cell dysfunction induced by infl ammation. EC -endothelial cell; TXA2 -thromboxane A2; PAF -platelet-activating factor; vWF -von Willebrand factor; PAI-1 -plasminogen activator inhibitor-1; VCAM-1 -vascular cell adhesion molecule-1; ICAM-1 -intercellular adhesion molecule-1; TF -tissue factor; EPCR -endothelial protein C receptor; TM -thrombomodulin; tPA -tissue plasminogen activator; PGI2 -prostacyclin.
Proinfl ammatory cytokines TNF-α, IL-1 and IL-6 are crucial in mediating the procoagulant eff ects of dysfunctional ECs. Vascular ECs respond to the cytokines expressed and released by infl ammatory cells, such as activated leukocytes, but can also release cytokines themselves thereby amplifying the haemostatic response in infl ammatory states (9) . ECs play an important role in all mechanisms that contribute to infl ammation-induced disturbance of the haemostatic system, including activation of platelets and other infl ammatory cells (in particular leukocytes), TF-mediated initiation and regulation of thrombin generation, as well as impaired function of physiologic anticoagulants and suppressed fi brinolytic activity. Physiologic inhibitors of coagulation, such as protein C (PC) system and tissue factor pathway inhibitor (TFPI) are connected to the endothelium, so that ECs play a key role in maintaining the function of these anticoagulant mechanisms. Also, as the main producer of fi brinolytic activator, i.e. tissue plasminogen activator (tPA) and inhibitor (PAI-1), ECs also have an obvious role in suppressed fi brinolytic activity in infl ammatory states. All these changes of ECs lead to the exposure of procoagulant components to blood and contribute to a prothrombotic state in infl ammatory states.
Platelet activation induced by infl ammation
Beside of an important role in haemostasis, platelets also play a relevant function in infl ammation acting as proinfl ammatory cells (10) . In physiological conditions, platelets circulate in a resting state, protected from activation by inhibitory mediators, such as nitric oxide (NO) and prostacyclin (PGI2) released from intact ECs. Numerous factors promote platelet activation during infl ammatory response. Such, EC dysfunction leads to increased platelet reactivity due to its elevated production of TXA2 and vWF and decreased production of PGI2. Upon vessel wall injury platelets rapidly adhere to the exposed subendothelial matrix. This process is mediated by several cellular receptors as well as various adhesive and regulatory proteins present on platelets or ECs thus allowing platelet-vessel wall interaction and subsequent thrombus formation (11) . Additionally, in the setting of infl ammationinduced activation of haemostasis, platelets can be directly activated with infl ammatory mediators such as proinfl ammatory cytokines or platelet-activating factor (PAF) in case of both non-infectious and infectious infl ammatory states (12) or with endotoxin in case of sepsis. Further, thrombin generated by activated coagulation cascade is one of the strongest platelet activators ( Figure 3 ).
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Resting platelet (disc-shape)
Activated platelet (spherical-shape)
Adhesion molecules
fibrinogen, fibronectin, vWF, GPIIb/IIIa, thrombospondin, vitronectin, P-selectin
Growth factors
PDGF, TGF-ß, EGF PGI2 -prostacyclin; PAF -platelet activating factor; GPIIb/IIIa -glycoprotein complex IIb/IIIa; PDGF -platelet derived growth factor; TGF-β -transforming growth factor-beta; EGF -epidermal growth factor; IL-1β -interleukin 1beta; PF-4 -platelet factor 4; RANTES -CCL5 chemokine; PAI-1 -plasminogen activator inhibitor 1; TF -tissue factor.
Coagulation factors
Upon activation, platelets undergo shape change from a disc-shaped cell into a spherical-shaped cell and express at their surface or secrete into the local environment a number of proinfl ammatory and procoagulant substances (13) , such as adhesion molecules, growth factors, cytokines and chemokines and certain coagulation factors and fi brinolytic inhibitor PAI-1 ( Figure 3 ). Additionally, platelets may generate procoagulant rich particles, called microparticles (MPs), a circulating cell fragments derived from activated or apoptotic cells. MPs contain negatively charged phospholipids essential for coagulation reactions and express TF on their surface (14, 15) and thus contribute to the prothrombotic state ( Figure 3 ). Individual platelet mediators modulate functions of other platelets, leukocytes and ECs. As an example, activated platelets secrete IL-1β, which is a major activator of ECs. This interaction of platelets with ECs results with secretion of IL-6 and monocyte chemotactic protein 1 (MCP-1) from ECs, as well as with the expression of adhesion molecules E-selectin, VCAM-1 and ICAM-1 on ECs (16) . Further, interaction of platelets with neutrophils promotes the recruitment of neutrophils into infl ammatory tissue thus directly participating in the host defence (17) . Interaction of platelets with infl ammatory cells such as leukocytes and ECs is mainly mediated through platelet P-selectin, a cell adhesion receptor localized in platelet's alphagranules (18, 19) . Upon platelet activation, P-selectin is rapidly translocated to the cell surface and serves as the receptor for its natural ligand, P-selectin glycoprotein ligand (PSGL-1) expressed on neutrophils, monocytes and ECs thus mediating platelet-leukocyte and platelet-EC interactions (18, 20) . Cellular interaction via P-selectin markedly enhances the production of proinfl ammatory cytokines and chemokines in neutrophils and mononuclear cells and increases the expression of adhesion molecules and TF on both leukocytes and ECs (5, 19) . The molecular mechanism of this eff ect relies on nuclear factor kappa B (NF-κB) activation induced by binding of activated platelets to neutrophils, mononuclear cells and ECs (13) .
Activation of the plasma coagulation cascade in infl ammation
The main mechanism of plasma coagulation cascade activation in infl ammation is mediated by TF (21) (22) (23) . TF is a transmembrane protein constitutively expressed by a variety of cell types including circulatory blood cells and ECs. Also, it is present in all blood-tissue barriers, such as adventitial layer of the vessel wall, so that coagulation can be initiated quickly once the endothelial barrier has been disrupted (24, 25) . However, in contrast to other coagulation factors, TF is normally not in direct contact with blood. Such, circulatory blood cells and ECs do not express TF under normal physiological conditions. However, when the integrity of the vessel wall is disrupted or if circulatory blood cells or ECs start to express TF in response to various proinfl ammatory stimuli, such as proinfl ammatory cytokines (TNF-α, IL-1 and IL-6) or endotoxin, TF expression is induced in diff erent cell types including leukocytes (predominantly monocytes and macrophages) and ECs. It enables that TF comes into direct contact with blood ( Figure 4 thereby generating thrombin (FIIa) whose key function is to convert fi brinogen to fi brin ( Figure 4) . Thrombin generated by activated coagulation cascade is a multifunctional molecule with many physiological functions. Such, thrombin has multilevel procoagulant activity. Besides it converts fibrinogen to fi brin, thrombin itself is one of the strongest platelet activators and also it is involved in feedback activation of coagulation by activating coagulation factors V, VIII, XI and XIII. Additionally, thrombin has relevant proinfl ammatory activity such as activation of infl ammatory cells (leukocytes and ECs) with consequent increased production of infl ammatory mediators and increased leukocytes adhesion and chemotaxis. Thrombin is an important regulator of cellular activation through binding to the protease-activated receptors (PARs) expressed on platelets, leukocytes and ECs. This represents the main mechanism by which activated haemostatic system augments initial infl ammatory response, as it will be discussed later. Additionally, activation of the coagulation cascade is markedly facilitated if a suitable phospholipid surface is available. Namely, coagulation reactions occur on membrane surfaces that contain negatively charged phospholipids. In normal physiological conditions, there are little negatively charged phospholipids exposed to the blood. However, both activated platelets and ECs transport their negatively charged phospholipids to the surface thus providing a phospholipid rich surface on their membrane. The phospholipid rich surface has an important role for assembly of complexes of activated coagulation factors. The presence of such a surface may accelerate several-fold the generation of thrombin and render the coagulation system less susceptible to fl uid-phase protease inhibitors.
Physiologic anticoagulants in infl ammation
The three major anticoagulant mechanisms involved in the regulation of coagulation activation are antithrombin (AT), PC system and tissue factor pathway inhibitor (TFPI). Antithrombin is the main inhibitor of thrombin, FXa and FIXa. PC pathway proteolytically cleaves activated coagulation cofactors FVa and FVIIIa. TFPI is the main inhibitor of the TF-FVIIa complex ( Figure 5 ). The main function of these coagulation inhibitors is to prevent blood clotting under physiological conditions and to slow down the activated coagulation cascade after vascular injury. Normal level and function of physiologic anticoagulants appears to be important in the defence against haemostatic abnormalities in infl ammatory states. There is increasing evidence that physiologic inhibitors of coagulation besides their anticoagulant actions also have important anti-infl ammatory functions (26) . However, the function of all three pathways can be impaired during infl ammation-induced disturbance of the haemostatic system. It represents an important mechanism of procoagulant state in infl ammation (27, 28) . 
Antithrombin
In infl ammatory states, the function of AT can be impaired as a result of increased consumption (due to activated coagulation cascade), decreased synthesis (as a result of a negative acute phase response) and increased degradation by proteolytic enzymes (elastase from activated neutrophils). Additionally, proinfl ammatory cytokines can cause reduced synthesis of glycosaminoglycans (GAGs), such as heparan sulphate on the endothelial surface, which also may contribute to the impaired AT function since endogenous GAGs act as physiolog-ic heparin-like cofactors thus promoting anticoagulant activity of AT (29) . Some of the anti-infl ammatory properties of AT are mediated by its anticoagulant actions in the coagulation cascade. By binding thrombin, AT contributes to reduced activation of proinfl ammatory cells (leukocytes, ECs and platelets). Further, increasing evidences suggest that AT possesses antiinfl ammatory action independent of its anticoagulant activity. Such, AT directly interacts with leukocytes by binding to their receptors thus blocking the interaction of leukocytes with ECs, i.e. leukocyte migration and adhesion to ECs (30) . Additionally, AT induces release of PGI2 from ECs. PGI2 acts as an inhibitor of platelet aggregation and blocks neutrophil adhering to blood vessels thus contributing to decreased production of proinfl ammatory cytokines and chemokines in neutrophils and ECs (31).
Protein C system
Among the three key natural anticoagulant mechanisms, the PC system appears to be the most important in regulating infl ammatory response and at the same time the most negatively infl uenced by infl ammatory states. Under physiological conditions, PC is activated by thrombin bound to endothelial cell membrane associated protein thrombomodulin (TM). Activated protein C (APC) with its cofactor protein S (PS) inactivates FVa and FVIIIa. There is increasing evidence that PC system also has important functions in modulating infl ammatory response (32, 33) , by its anti-infl ammatory and profi brinolytic activities (34, 35) . Anti-infl ammatory actions of APC include inhibition of cytokine (TNF-α, IL-1, IL-6) production by monocytes/macrophages (36), inhibition of chemotaxis and adhesion of leukocytes to endothelium and suppression of NF-κB transcription (34) . It is considered that anti-infl ammatory eff ects of APC are mediated by the endothelial protein C receptor (EPCR) (37) . Binding of APC to EPCR infl uences gene expression profi les of cells by blocking NF-κB nuclear translocation. This results with limited production of proinfl ammatory cytokines and expression of cell surface adhesion molecules in ECs (38) . Further, APC has profi brinolytic action mediated by neutralization of PAI-1 activity. In addition to these anti-infl ammatory actions of APC, particular components of the PC system can also contribute to attenuated infl ammatory response. Besides an essential role of TM in PC system activation, it also suppresses infl ammation by direct and indirect mechanisms (39) . Thrombomodulin-mediated binding of thrombin attenuates proinfl ammatory eff ects of thrombin, such as platelet activation, chemotaction of monocytes and neutrophils, upregulation of leukocyte adhesion molecules and activation of infl ammatory cells by binding to PARs (40) . Also, by binding to thrombin, TM blocks its procoagulant action i.e., ability to clot fi brinogen. Additionally, the thrombin-TM complex activates thrombin-activatable fi brinolysis inhibitor (TAFI), an important inhibitor of fi brinolysis but also a molecule responsible for inactivation of complement component C5a, an anaphylatoxin created during complement activation (41) . Considering that TM is abundantly present in the microcirculation, TAFI-mediated inactivation of C5a would be expected to protect against complement-mediated injury of the microvasculature (2). As in case of AT, function of the PC system may be impaired because of decreased synthesis or increased consumption and degradation in infl ammatory states. Furthermore, downregulation of TM and EPCR at the endothelial surface caused by proinfl ammatory cytokines (TNF-α, IL-1β) and neutrophil elastase from activated neutrophils may further negatively aff ect function of the PC system (42) . In addition, increased plasma levels of C4b-binding protein (C4B-BP) as an acute phase reactant can result in a relative PS defi ciency due to decreased levels of free PS, which further can contribute to a procoagulant state (6) . Impairment of the PC system appears to play an important role in the pathogenesis of sepsis and associated organ dysfunction (43, 44) , as it will be discussed later in the text.
Tissue factor pathway inhibitor (TFPI)
The third physiological anticoagulant mechanism is TFPI (45), a serine protease inhibitor attached to the endothelium via GAGs and secreted by ECs. As in case of AT, proinfl ammatory cytokines can cause reduced synthesis of GAGs on the endothelial surface, which may aff ect the function of TFPI. However, relatively little is known about the impact of infl ammation on TFPI function. Its role in the regulation of infl ammation-induced activation of haemostasis is not completely clear mostly because the majority of TFPI is associated with the vessel endothelium and direct assays of endogenous TFPI activity in vivo are not routinely available. Because of that it makes very diffi cult to assess whether this anticoagulant pathway is modulated by infl ammation (46) . Clinical experiments showed that administration of recombinant TFPI blocked infl ammation-induced thrombin generation in humans (47, 48) . These results suggest that high concentrations of TFPI are capable of modulating TFmediated activation of coagulation. However, the endogenous concentration of TFPI is considered not to be capable of regulating coagulation activation during infl ammation.
Fibrinolytic system
Haemostasis is further controlled by the fi brinolytic system, in which the key enzyme, plasmin degrades fi brin clot. Plasmin is generated from plasminogen by activators such as tPA and urokinase plasminogen activator (uPA). The main inhibitor of these plasminogen activators is PAI-1. Binding to plasminogen activators, PAI-1 causes their inactivation thus suppressing the fi brinolytic activity. Inhibition of the fi brinolytic system is another important component in the haemostatic disorder during infl ammatory states. The initial acute fi brinolytic response in infl ammatory states is a transient increase in fi brinolytic activation mediated by the immediate release of tPA from vascular ECs. However, this increased plasminogen activation is followed by delayed but sustained increase in the main fi brinolytic inhibitor PAI-1. It results with signifi cant suppression of fi brinolytic activity and subsequent inadequate fi brin removal. The main regulators of PAI-1 activity are proinfl ammatory cytokines TNF-α and IL-1β (49), which induce the production of PAI-1 in vascular ECs ( Figure 6 ). Further, platelet alpha granules also contain large amounts of PAI-1 and release it upon their activation. This may further increase the levels of PAI-1 and contribute to the fi brinolytic suppression in infl ammatory states. Additionally, dysfunction of ECs induced by infl ammation may also result with delayed but sustained decreased production of tPA ( Figure 6 ). Individual fi brinolytic components may also modulate the infl ammatory response by their eff ect on infl ammatory cell recruitment and migration. In particular, uPA and its receptor urokinase plasminogen activator receptor (uPAR) are involved in these processes. Such, uPAR expressed on leukocytes mediates leukocyte adhesion to the vascular wall thus aff ecting cell migration (7, 50) . 
Mechanisms by which activated haemostatic system infl uences infl ammatory response
The communication between infl ammation and haemostasis is a bidirectional process, so activated haemostatic system also considerably modulates infl ammatory activity. Individual components of the activated haemostatic system, such as activated coagulation factors thrombin, FXa and TF-FVIIa complex can directly stimulate cells involved in infl ammatory response (platelets, leukocytes and ECs) with consequent increased production of proinfl ammatory mediators by these cells. The key mechanism by which activated coagulation factors augment infl ammatory response is by their binding to PARs. The PAR family of receptors consists of four members, PAR-1 to PAR-4, which are localized on diff erent cell types such as ECs, leukocytes, platelets, fi broblasts and smooth muscle cells. (24, 51) . These receptors serve as their own ligand, so that proteolytic cleavage of PAR by an activated coagulation factor activates the same receptor. Coagulation proteases activate PARs in a common way. The receptor is proteolitically cleaved at a specifi c site within its intracellular Nterminus. It leads to exposure a new terminus that serves as a ligand for the same receptor and results with a transmembrane signal transduction and consequent increased infl ammatory response (7). PAR-1, 3 and 4 are thrombin receptors, while PAR-2 receptor can be activated by the TF-FVIIa complex or FXa. Binding of an activated coagulation factor to the individual PAR receptor results in upregulation of infl ammatory responses by inducing the production of proinfl ammatory mediators, such as cytokines, chemokines, growth factors and cell adhesion molecules. Such, PARs seem to play an important role in linking infl ammation and haemostasis (52) . Activated platelets also play an important role in enhanced infl ammatory response, in particular in chronic infl ammatory states such as atherosclerosis, as it will be discussed in the next section. Further, fi brinogen as well as fi brin generated by activated coagulation cascade also mediates cellular activation in infl ammation. Such, fi brinogen and fi brin are capable of recruiting and activating leukocytes by binding to the specifi c receptors, such as toll-like receptors (TLR) expressed at the surface of infl ammatory cells (53, 54) . Both fi brinogen and fibrin stimulate the expression of proinfl ammatory cytokines (TNF-α, IL-1β) on monocytes and chemokines (IL-8, MCP-1) on ECs and fi broblasts (55) .
Specifi c features of haemostatic disorder induced by infl ammation in acute arterial thrombosis and systemic infl ammatory response to infection (sepsis)
Atherosclerosis and consequent acute arterial thrombosis and sepsis represent the examples of the two clinical conditions in which close relationship between infl ammation and haemostasis considerably contributes to disease severity. Because, in the next section of this article the most important features in the bidirectional relationship between infl ammation and haemostasis in these two pathophysiological states will be discussed.
Relationship between infl ammation and haemostasis in acute arterial thrombosis
Atherosclerosis is a chronic infl ammatory process (56) in which thrombus formation on a ruptured atherosclerotic plaque is the pathological basis of an acute arterial thrombotic event such as myocardial infarction (10, 57) . Infl ammation plays an important role in atherosclerotic process, including fatty streak formation, plaque destabilization and subsequent thrombosis (58, 59) . However, the mechanisms of arterial thrombosis involve not only infl ammation, but rather a combination of infl ammatory and prothrombotic factors that considerably aff ect each other (5, 60) . Such, platelets have an important role in the pathogenesis of arterial thrombosis including atherosclerotic plaque formation as well as its progression to acute thrombotic event (16, 60) . It has been shown that platelets rapidly adhere to the injured endothelium (61) . In an atherosclerotic process, erosion of the vessel intimae exposes subendothelial collagen to the blood, which causes platelet adhesion, activation and subsequent aggregation (62) . Once recruited to the atherosclerotic lesion, platelets become activated and express proinfl ammatory molecules that can additionally promote chemoattraction of leukocytes (PAF, macrophage infl ammatory protein-1 (MIP-1)), stimulation of smooth muscle cells, fi broblast proliferation (PDGF, serotonin, TGF-β) and collagen synthesis. Additionally, activated platelets release proinfl ammatory cytokines (CD40 ligand, IL-1β) and chemokines (platelet factor-4 (PF-4), RANTES) which support monocyte recruitment to atherosclerotic plaques. Platelet adhesion to the subendothelial surface supports leukocyte rolling and extravasation through interaction of platelet P-selectin with PSGL-1 receptor expressed on leukocytes. Also, as it has already been told, activated platelets contain procoagulant molecules that directly contribute to activation of the haemostatic system. Further, expression of the procoagulant material, in particular TF, by infl ammatory cells in the unstable or ruptured plaque acts as one of the main ac-tivators of the coagulation cascade (63) . Induced expression of TF on ECs, monocytes and smooth muscle cells in atherosclerotic plaques is mostly mediated by sustained increased levels of proinfl ammatory cytokines TNF-α and IL-1β (64) . Since these cells respond to infl ammatory signals within the plaque, its rupture promotes increased cell expression of TF (60, 63) . It has been shown that mononuclear cells in atherosclerotic plaque express much more TF than native mononuclear cells in the circulation due to sustained exposure to proinfl ammatory mediators in the plaque, such as cytokines (IL-1, IL-6, TNF-α) and chemokines (PDGF, MCP-1). It is apparent that circulating monocytes represent one of the principal players in the crosstalk between infl ammation and activated coagulation system in an atherosclerotic process. At the same time with an activation of the coagulation system in a progressive atherosclerotic process, there is also a reduced function of anticoagulant PC system mostly due to downregulated TM and EPCR expression in ECs overlying a plaque in coronary arteries (42) . Downregulation of these two important components of the PC system is mostly mediated by sustained increased levels of proinfl ammatory cytokines TNF-α and IL-1β. It may result with decreased PC activation and potentially lead to more extensive thrombin generation at the site of the atherosclerotic lesion. It appears that patients with heterozygous mutation in the TM gene have a higher risk of myocardial infarction (65) . As it has already been told, besides of its anticoagulant activity, TM also has anti-infl ammatory actions. Additionally, sustained increased levels of proinfl ammatory cytokines TNF-α and IL-1β can cause increased production of PAI-1 in ECs within the plaque. It contributes to suppressed fi brinolytic activity in atherosclerotic process.
Relationship between infl ammation and haemostasis in sepsis
Another example of close interaction between immune and haemostatic system is obvious in sepsis. Sepsis is a clinical syndrome characterized by an excessive systemic host response to infection resulting with an uncontrolled activation of infl ammatory response. Since the immune and haemostatic systems are tightly linked, an excessive infl ammatory response can also lead to systemic activation of the haemostatic system. In fact, local activation of the coagulation in septic patients is an integral component of the host defence as an attempt to eradicate the invading microorganism. However, an exaggerated response to infection can lead to a situation in which systemic activation of the haemostatic system itself contributes to disease severity, causing a syndrome known as disseminated intravascular coagulation (DIC) (24, 66) . Patients with severe form of DIC may clinically present with manifest thromboembolic disease or clinically less apparent microvascular fi brin deposition that contribute to the multiple organ dysfunction (67, 68) . With the progression of sepsis, coagulopathy becomes increasingly more severe. Progression of the haemostatic disorder in sepsis results in the widespread formation of fi brin clots, microvascular occlusion and reduced oxygen delivery to cells and tissues with subsequent organ dysfunction (67) . DIC has been shown to be an important independent predictor of organ failure and mortality in septic patients (69, 70) . The majority of septic patients have coagulation abnormalities (71) ranging from subtle not clinically manifested activation of coagulation to severe coagulation disorders such as fulminant form of DIC, characterized by simultaneous microvascular thrombosis and profuse bleeding from various sites thus being a driving force in acute organ dysfunction and death (68, 69, 71) . The main mechanisms responsible for this severe haemostatic disorder in septic patients are mediated by excessive and uncontrolled actions of infl ammatory mediators, in particular, proinfl ammatory cytokines. These infl ammatory mediators activate coagulation system by TF-mediated pathway and at the same time signifi cantly downregulate physiologic anticoagulant pathways (72) . Thus the procoagulant activity of the haemostatic system exceeds the capacity of the physiologic anticoagulants to control the activation of coagulation. Conversely, poorly regulated activity of the haemostatic system in turn amplifi es the infl ammatory process causing additional organ injury. Additionally, infectious agent itself can cause endothelial damage, which also contributes to the prothrombotic state in severe infection. The mod-el of endotoxin-induced activation of the haemostatic system is the best studied model of the complex interactions between infl ammation and haemostasis. Endotoxin is the lipopolysaccharide compound from gram negative bacteria responsible for the severe infection such as sepsis. In blood, endotoxin directly binds to CD14 receptor on monocytes and binds to ECs after complexing with lipopolysaccharide binding protein (LBP) and toll-like receptor 4 (TLR-4). Through these interactions, endotoxin induces a number of signalling pathways leading to the activation of NF-κB with consequent transcription of genes coding a number of proinfl ammatory mediators (73) . Endotoxin also has direct positive eff ect on markedly increased TF expression on infl ammatory cells such as leukocytes and ECs. Further, the fi brinolytic system is directly infl uenced by the septic process. In most patients with sepsis, fi brinolytic activity is suppressed, while the coagulation activation still proceeds. As in other infl ammatory states, the main cause of decreased fi brinolytic activity in septic patients is increased activity of PAI-1 due to sustained actions of proinfl ammatory cytokines. One of the important mechanisms of disturbed regulation of the haemostatic system in septic patients is signifi cantly reduced function of the PC system. Clinically, there is a correlation between the degree of PC reduction and mortality of septic patients (40, 74) . It has been shown that in patients with severe sepsis, the PC system is malfunctioning at all levels, including decreased synthesis, increased consumption and degradation and downregulation of TM and EPCR at the endothelial surface. Understanding the basic mechanisms of activation of the haemostatic system and its derangements in sepsis is crucial for the development of potential new therapeutic strategies (75) . The key treatment of patients with sepsis is to treat the underlying infection with appropriate antibiotics and additional supportive treatment aimed at circulatory and respiratory support. However, abnormalities of the haemostatic system may proceed even with proper treatment. In these cases, supportive measures to manage haemostatic disorder may be considered. Since infl ammation and haemostatic system are processes that function in a positive feedback loop, it is reasonable to believe that both are an appropriate target for intervention to reduce mortality in these patients. Improved understanding of the molecular mechanisms in the bidirectional interaction between infl ammation and haemostasis has led to the development of new therapeutic approach for the treatment of severe sepsis. Among these agents, recombinant human activated protein C (rHuAPC) has shown the most promising results by signifi cant reducing mortality in patients with severe sepsis (34, 76) . It is considered that these benefi cial eff ects of rHuAPC can be attributed to anti-infl ammatory properties in addition to its anticoagulant activity. However, although therapeutic administration of rHuAPC has been advocated in guidelines for the treatment of the severe sepsis as an additional treatment strategy (77) , there is currently debate on rHuAPC efficacy since recent fi ndings have cast some doubt on its usefulness (78) (79) (80) .
Conclusion and perspectives
Improved understanding of the molecular mechanisms that play a role in the bidirectional relationship between infl ammation and haemostasis could help in the clinical management of patients by identifying of new potential therapeutic targets that can modify excessive and inappropriate activation or deregulation of both systems. On the basis of experimental and clinical studies, it is likely that simultaneous modulation of both infl ammatory and haemostatic activities, rather than specific therapy aimed at only one component could be more successful in the treatment of clinical states and diseases in which close link between infl ammation and haemostasis considerably contribute to the pathogenesis or progression of disease. However, despite the impressive progress in understanding the molecular mechanisms linking infl ammation and haemostasis during recent years, many questions remain open. Therefore, further study of the complex molecular mechanisms linking immune and haemostatic systems deserves attention of both medical experts and scientists.
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